NCT05523375

Brief Summary

The primary aim is to test the effectiveness of an innovative 24-month pragmatic and scalable weight-loss centric approach using a collaborative care model that connects patients with a non-Primary Care Practitioner (PCP) health coach who delivers care remotely to patients through the patient portal of an electronic medical record (EMR).

Trial Health

55
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
352

participants targeted

Target at P75+ for not_applicable obesity

Timeline
Completed

Started Aug 2022

Typical duration for not_applicable obesity

Geographic Reach
1 country

1 active site

Status
active not recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

August 29, 2022

Completed
Same day until next milestone

Study Start

First participant enrolled

August 29, 2022

Completed
2 days until next milestone

First Posted

Study publicly available on registry

August 31, 2022

Completed
3.6 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 31, 2026

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

March 31, 2026

Completed
Last Updated

March 17, 2025

Status Verified

March 1, 2025

Enrollment Period

3.6 years

First QC Date

August 29, 2022

Last Update Submit

March 13, 2025

Conditions

Outcome Measures

Primary Outcomes (1)

  • Body weight (Percent Change)

    Body weight is measured in light indoor clothes and is obtained from the electronic medical record.

    Percent (%) Change from Baseline to Month 24

Secondary Outcomes (14)

  • Body weight (kg)

    Change in kg from Baseline to Month 24

  • Systolic Blood Pressure

    Change from Baseline to Month 24

  • Diastolic Blood Pressure

    Change from Baseline to Month 24

  • HbA1c

    Change from Baseline to Month 24

  • Total Cholesterol

    Change from Baseline to Month 24

  • +9 more secondary outcomes

Study Arms (2)

Intensive Lifestyle Intervention

EXPERIMENTAL

The intervention arm receives a comprehensive, "high-intensity" program, as recommended first-line therapy by the 2013 American Heart Association/American College of Cardiology/The Obesity Society Obesity Guidelines, delivered remotely using eHealth technology, by trained health coaches embedded in the Digital Medicine Group in the Ochsner Health System. The intervention includes remote sessions with the health coach using evidence-based components such as the use of portion control and various behavioral strategies .Patients in the Intervention arm attend weekly sessions in the first six months, followed by monthly sessions for the remaining 18 months.

Behavioral: Intensive Lifestyle Intervention

Usual Care

NO INTERVENTION

Patients in the usual care arm will receive their normal, usual care from their primary care team.

Interventions

Trained health coaches deliver the active intervention - a comprehensive, "high-intensity" program, as recommended first-line therapy by the 2013 American Heart Association/American College of Cardiology/The Obesity Society Guidelines.

Intensive Lifestyle Intervention

Eligibility Criteria

Age40 Years - 70 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • years of age
  • Self-identify as Black/African American
  • Obesity (BMI 30.0-50.0 kg/m2)
  • Type II diabetes (based on ICD-10 codes, fasting plasma glucose ≥126 mg/dL, HbA1c ≥6.5%, 2-h plasma glucose during 75-g Oral Glucose Tolerance Test (OGTT) ≥200 mg/dL, or a random plasma glucose ≥200 mg/dL in a patient with classic symptoms of hyperglycemia or hyperglycemic crisis) or pre-diabetes (based on ICD-10 codes, fasting glucose 100-125 mg/dL or HbA1c 5.7-6.4% or 2-h glucose during 75-g OGTT 140-199 mg/dL)
  • Has an internet-connected device and is willing to use it for intervention delivery
  • Patient in the Ochsner Health System with an active MyOchsner portal account, or willing to create one
  • Acknowledgement from their Ochsner primary care practitioner that there are no known contraindications to the patient's participation
  • Have weight measured at an Ochsner clinic within 4 weeks of screening
  • Resident of Louisiana
  • Be able to provide informed consent
  • Willing to change diet and/or physical activity

You may not qualify if:

  • Body weight ≥ 400 lbs.
  • Current use of weight loss medication or recent weight loss (net loss \>10 lbs in the last six months)
  • Currently participating in a structured weight loss program
  • Plans to move from the area within 2 years
  • Given birth within the past year, is currently pregnant or breastfeeding or plans to become pregnant within 2 years
  • Past bariatric surgery or plans for bariatric surgery within 2 years
  • Disease/condition that is life threatening or can interfere with or be aggravated by exercise or weight loss

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Pennington Biomedical Research Center

Baton Rouge, Louisiana, 70808, United States

Location

Related Publications (1)

  • Katzmarzyk PT, Price-Haywood EG, Apolzan JW, Denstel KD, Drews KL, Farris E, Harden-Barrios J, Hearld LR, Mire EF, Martin CK, Newton RL, Pisu M. Improving weight loss and cardiometabolic risk in black patients with diabetes or pre-diabetes: Rationale and protocol for a digital medicine hybrid type 1 implementation trial. Contemp Clin Trials. 2025 Feb;149:107806. doi: 10.1016/j.cct.2024.107806. Epub 2025 Jan 3.

MeSH Terms

Conditions

ObesityDiabetes Mellitus, Type 2Prediabetic State

Condition Hierarchy (Ancestors)

OverweightOvernutritionNutrition DisordersNutritional and Metabolic DiseasesBody WeightSigns and SymptomsPathological Conditions, Signs and SymptomsDiabetes MellitusGlucose Metabolism DisordersMetabolic DiseasesEndocrine System Diseases

Study Officials

  • Peter T Katzmarzyk, PhD

    Pennington Biomedical Research Center

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Associate Executive Director for Population and Public Health

Study Record Dates

First Submitted

August 29, 2022

First Posted

August 31, 2022

Study Start

August 29, 2022

Primary Completion

March 31, 2026

Study Completion

March 31, 2026

Last Updated

March 17, 2025

Record last verified: 2025-03

Data Sharing

IPD Sharing
Will share

A de-identified individual-level dataset will be made available to researchers making a reasonable request and upon approval of the PROPEL-IT Publications Committee. Data will be made available 1 year after publication of the primary outcomes manuscript.

Shared Documents
STUDY PROTOCOL, SAP, ICF
Time Frame
Data will be made available upon reasonable request to the Principal Investigator 1 year after the publication of the Primary Outcomes manuscript for up to 5 years.
Access Criteria
Access to the data must be approved by the PROPEL-IT Publications Committee.

Locations